Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact of Alzheimer’s disease makes it a major healthcare challenge. 

IGC Pharma is one of the companies hoping to provide solutions for millions of suffering Americans. It is a pharmaceutical company focused on developing innovative therapies for various medical conditions and fields, including Alzheimer’s disease, chronic pain and women’s health.

IGC-AD1 is undergoing extensive clinical trials to evaluate its effectiveness and safety in treating Alzheimer’s disease. The phase two clinical trial, initiated in 2023, encompasses 20 sites across the United States and Canada. 

Pre-clinical studies of IGC-AD1 have demonstrated its potential in reducing the production of Aβ40 peptide and inhibiting the aggregation of Aβ42, both of which are associated with Alzheimer’s.